Prostate-specific antigen density as a predictor of recurrence-free survival following combined hormonal-radiation therapy of localized prostate cancer

Background. Prostate cancer is amongst one of the most prevalent cancers in men worldwide. Combined hormonal-radiation therapy has become a standard of care for localized prostate cancer definitive treatment. As many as 30 % of men are at risk for disease progression within 10 years following radical treatment.

Aim. To assess the significance of prostate-specific antigen (PSA) density as a predictor of recurrence-free survival following combined hormonal-radiation therapy in patients with localized prostate cancer.

Materials and methods. We conducted a retrospective study of 272 patients with clinically localized prostate cancer treatment results who received combined hormonal-radiation therapy between January 1996 and December 2016.

Results. On the basis of our study, we confirmed high prognostic value of PSA density among patients with localized prostate cancer who received combined hormonal-radiation treatment. We utilized ROC-analysis in order to determine the threshold value of the PSA density index – 0.376 ng/ml/cm³, exceeding of which was associated with statistically significant reduction in the recurrence-free survival rate. The area under the curve was 0.711 (95 % confidence interval 0.653–0.764; p <0.0001). The risk of recurrence increased with rising of PSA density.

Conclusion. PSA density has proven to be a reliable tool for assessing the risk of prostate cancer recurrence among patients with localized prostate cancer who have undergone combined hormonal-radiation therapy.

1. Rider J.R., Wilson K.M., Sinnott J.A. et al. Ejaculation frequency and risk of prostate cancer: updated results with an additional decade of follow-up. Eur Urol 2016;70(6):974–82. DOI: 10.1016/j.eururo.2016.03.027

2. Nosov D.A., Volkova M.I., Gladkov O.A. et al. Practical Guidelines for Prostate Cancer Drug Treatment. Zlokachestvennye opukholi. Prakticheskie rekomendatsii RUSSCO = Malignant tumors. RUSSCO Practical Guidelines 2021;10(3s2–1):556–72. (In Russ.). DOI: 10.18027/2224-5057-2020-10-3s2-33

3. Cornford P., van den Bergh R.C.N., Briers E. et al. EAU-EANMESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: treatment of relapsing and metastatic prostate cancer. Eur Urol 2021;79(2):263–82. DOI: 10.1016/j.eururo.2020.09.046

4. Parker C., Gillessen S., Heidenreich A. et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v69–77. DOI: 10.1093/annonc/mdv222

5. National Comprehensive Cancer Network (NCCN®) clinical practice guidelines in oncology. Prostate cancer, version 2.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

6. Hull G.W., Rabbani F., Abbas F. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167(2 Pt 1):528–34. DOI: 10.1097/00005392-200202000-00018

7. Han M., Partin A.W., Zahurak M. et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169(2):517–23. DOI: 10.1097/01.ju.0000045749.90353.c7

8. Mottrie A., De Naeyer G., Novara G. et al. Robotic radical prostatectomy: a critical analysis of the impact on cancer control. Curr Opin Urol 2011;21(3):179–84. DOI: 10.1097/MOU.0b013e328344e53e

9. Park J.S., Koo K.C., Choi I.Y. et al. Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy: a K-CaP registrybased analysis. Medicine (Baltimore) 2019;98(45):e17931. DOI: 10.1097/MD.0000000000017931

10. Bruno S.M., Falagario U.G., d’Altilia N. et al. PSA density help to identify patients with elevated PSA due to prostate cancer rather than intraprostatic inflammation: a prospective single center study. Front Oncol 2021;11:693684. DOI: 10.3389/fonc.2021.693684

11. Catalona W.J., Smith D.S., Ratliff T.L. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324(17):1156–61. DOI: 10.1056/NEJM199104253241702

12. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7–30. DOI: 10.3322/caac.21387

13. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005;104(6):1129–37. DOI: 10.1002/cncr.21324

14. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11(4):239–53. DOI: 10.1038/nrc3007

15. Kupelian P.A., Mahadevan A., Reddy C.A. et al. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology 2006;68(3):593–8. DOI: 10.1016/j.urology.2006.03.075

16. Mottet N., van den Bergh R.C.N., Briers E. et al. EAU-EANMESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79(2):243–62. DOI: 10.1016/j.eururo.2020.09.042

17. Aref I., Eapen L., Agboola O. et al. Is prostate specific antigen density an important prognostic indicator for patients with prostate cancer treated with external beam therapy? Br J Radiol 1998;71(848):868–71. DOI: 10.1259/bjr.71.848.9828800

18. Ingenito A.C., Ennis R.D., Hsu I.C. et al. Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer. Urology 1997;50(1):73–8. DOI: 10.1016/S0090-4295(97)00202-1

19. D’Amico A.V., Propert K.J. Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 1996;35(2):273–9. DOI: 10.1016/0360-3016(95)02389-5

20. Corn B.W., Hanks G.E., Lee W.R. et al. Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. J Urol 1995;153(6):1855–9. DOI: 10.1016/S0022-5347(01)67331-2